156
Views
11
CrossRef citations to date
0
Altmetric
LUPEOL ENHANCES RADIOSENSITIVITYIN LIVER CANCER

Lupeol enhances radiosensitivity of human hepatocellular carcinoma cell line SMMC-7721 in vitro and in vivo

, , , , , & show all
Pages 202-208 | Received 11 Apr 2014, Accepted 10 Sep 2014, Published online: 27 Jan 2015
 

Abstract

Purpose: To investigate the effect of lupeol, a pentacyclictriterpene, on the radiosensitivity of a human hepatocellular carcinoma (HCC) in vitro and in vivo xenografts.

Methods: SMMC-7721 cells were exposed to γ-radiation with or without lupeol and assayed for proliferation, clonogenic survival, apoptosis and cell cycle distribution. The cells were also analyzed by Western blotting for the expression levels of the proteins involved in apoptosis. Finally radiosensitization by lupeol was assessed in HCC xenograft model.

Results: Lupeol further suppressed the proliferation and colonogenic survival of the SMMC-7721 cells exposed to γ-radiation. It could also induce the accumulation of cells in G2/M phase together with γ-radiation. The data also indicated that lupeol sensitized SMMC-7721 cells exposed to γ-radiation to apoptosis and activated the apoptotic proteins including caspase-9 and PARP. Administration of lupeol with radiation in HCC xenograft model produced a significant tumor growth delay compared with radiation or lupeol alone and was well tolerated.

Conclusion: Lupeol significantly enhanced the radiosensitivity of SMMC-7721 cells in vitro and in vivo. The mechanisms involved could be cell cycle arrest and induction of apoptosis. Our studies suggest that lupeol has the potential to be developed as an adjuvant for radiotherapy in HCC.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

This work has been supported by the funding for science and technology supporting in Huai'an (HAS2013010) and the start-up funds in science research from Huai'an Second People's Hospital (YK201217).

Supplementary Material Available Online

Supplementary Figures 1 and 2.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.